JANX Insider Trading

Insider Ownership Percentage: 29.40%
Insider Buying (Last 12 Months): $53,700,000.00
Insider Selling (Last 12 Months): $188,270,185.71

Janux Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Janux Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$1.03MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M$0$100MTotal Insider BuyingTotal Insider Selling

Janux Therapeutics Share Price & Price History

Current Price: $44.76
Price Change: Price Decrease of -0.032 (-0.07%)
As of 01/31/2025 02:05 PM ET

This chart shows the closing price history over time for JANX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJan$44.79Closing price on 01/30/25:

SEC Filings (Institutional Ownership Changes) for Janux Therapeutics (NASDAQ:JANX)

75.39% of Janux Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at JANX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$4.27Mbought$408ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
Janux Therapeutics logo
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Read More on Janux Therapeutics

Today's Range

Now: $44.76
Low: $43.55
High: $46.10

50 Day Range

MA: $51.74
Low: $40.18
High: $66.84

52 Week Range

Now: $44.76
Low: $7.79
High: $71.71

Volume

279,837 shs

Average Volume

1,114,121 shs

Market Capitalization

$2.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.23

Who are the company insiders with the largest holdings of Janux Therapeutics?

Janux Therapeutics' top insider investors include:
  1. Ra Capital Management, LP (Director)
  2. Ventures Xi LP Avalon (Major Shareholder)
  3. Jay Lichter (Director)
  4. Tighe Reardon (CFO)
  5. David Alan Campbell (CEO)
  6. Andrew Hollman Meyer (Insider)
Learn More about top insider investors at Janux Therapeutics.

Who are the major institutional investors of Janux Therapeutics?

Janux Therapeutics' top institutional shareholders include:
  1. abrdn plc — 0.12%
  2. Rhumbline Advisers — 0.07%
  3. Lester Murray Antman dba SimplyRich — 0.05%
  4. Nisa Investment Advisors LLC — 0.02%
  5. China Universal Asset Management Co. Ltd. — 0.02%
  6. Legato Capital Management LLC — 0.01%
Learn More about top institutional investors of Janux Therapeutics stock.

Which institutional investors are selling Janux Therapeutics stock?

In the last quarter, JANX stock was sold by these institutional investors:
  1. Nisa Investment Advisors LLC
  2. Chicago Partners Investment Group LLC
Within the last year, company insiders that have sold Janux Therapeutics company stock include:
  1. Ra Capital Management, LP (Director)
  2. Ventures Xi LP Avalon (Major Shareholder)
  3. Jay Lichter (Director)
  4. Tighe Reardon (CFO)
  5. David Alan Campbell (CEO)
Learn More investors selling Janux Therapeutics stock.

Which institutional investors are buying Janux Therapeutics stock?

In the last quarter, JANX stock was acquired by institutional investors including:
  1. abrdn plc
  2. Lester Murray Antman dba SimplyRich
  3. Legato Capital Management LLC
  4. Chicago Capital LLC
  5. Avanza Fonder AB
  6. China Universal Asset Management Co. Ltd.
  7. Rhumbline Advisers
During the last year, these company insiders have bought Janux Therapeutics stock:
  1. Ra Capital Management, LP (Director)
  2. Ventures Xi LP Avalon (Major Shareholder)
Learn More investors buying Janux Therapeutics stock.